Focal Segmental Glomerulosclerosis And Minimal Change Disease (Anti-Nephrin Positive)
VERAVera TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for Atacicept in Focal Segmental Glomerulosclerosis And Minimal Change Disease (Anti-Nephrin Positive). The expected timing is based on the latest available company guidance and may change.
08/10/26:- PIONEER enrollment complete. Additional clinical results expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.